ImmuPharma (LON:IMM) Stock Price Up 25.3% - Time to Buy?

Key Points

• ImmuPharma's stock price surged by 25.3% during trading on Monday, reaching a high of GBX 19.35 ($0.26) from a previous close of GBX 13.98 ($0.19).
• A total of 65.6 million shares were traded, marking a significant increase of 677% compared to the average session volume.
• The company's latest quarterly earnings report indicated a negative EPS of GBX (0.38) and an exceptionally high net margin of 3,519.56%.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price rose 25.3% during trading on Monday . The company traded as high as GBX 19.35 ($0.26) and last traded at GBX 17.51 ($0.24). Approximately 65,638,188 shares were traded during mid-day trading, an increase of 677% from the average daily volume of 8,446,959 shares. The stock had previously closed at GBX 13.98 ($0.19).

ImmuPharma Stock Down 21.1%

The stock has a 50 day moving average of GBX 3.68 and a 200 day moving average of GBX 3.09. The company has a market capitalization of £58.76 million, a price-to-earnings ratio of -1,321.12 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, sell-side analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.